The Role of Ribose in Patients Diagnosed With Fibromyalgia

Bioenergy Life Science, Inc.200 enrolled

Overview

The purose of this research study is to determine the potential benefit of D-ribose, a nutritional supplement (a sugar), versus a placebo (another sugar) in people with fibromyalgia.

Two hundred to three hundred subjects (equally distribued between placebo and D-ribose) between 18-78 years of age will comprise this study. The final numbers enrolled will depend upon obtaining approximately 100 subjects that can display a high degree of compliance to TID dosing with approximately equal balance between the active and placebo arms.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

QUADRUPLE

Enrollment

200

Conditions

Fibromyalgia

Interventions

D-riboseDIETARY_SUPPLEMENT

5 grams administered orally TID

dextroseOTHER

5 grams orally TID

Eligibility

Sex: ALLMin age: 18 YearsMax age: 78 Years

Medical Language ↔ Plain English

Inclusion Criteria: * previous diagnosis of fibromomyalgia by a MD * Has been diagnosed with fibromyalgia and are over 18 years of age * Does live in the United States Exclusion Criteria: * does NOT have severe medication/chemical/supplement sensitivities * does NOT have insulin dependent diabetes or other severe illnesses (cancer, hepatitis, congestive heart failure) * does NOT have rheumatoid arthritis or gout * previous use of ribose

Locations (1)

Bioenergy Life Science, Inc.

Minneapolis, Minnesota, United States

Outcomes

Primary Outcomes

Significant reduction in symptoms of pain and fatigue

Time frame: 3 weeks

Secondary Outcomes

Demonstrate an improvement in ones quality of life

Time frame: 3 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.